Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Medulloblastoma × arginyllysine × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2 NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 3 Neuroblastoma 1 Meningioma 1 Medulloblastoma 1 Gastro-enteropancreatic neuroendocrine tumor 1 Carcinoid Tumor 1

Interventions

pentetreotide 1 olaparib 1 lutetium Lu 177 dotatate 1 gallium Ga 68 dotatate 1 arginyllysine 1 Whole Body Imaging 1 Magnetic Resonance Spectroscopy 1 Amino Acids 1 90Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed

39 enrolled 9 charts

CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡